These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10533697)

  • 1. In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics.
    Iyer GR; Bellantone RA; Taft DR
    J Pharmacokinet Biopharm; 1999 Feb; 27(1):45-66. PubMed ID: 10533697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjects.
    Taft DR; Nordt S; Iyer GR; Schwenk MH
    Biopharm Drug Dispos; 1998 Sep; 19(6):373-80. PubMed ID: 9737818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation of the pharmacokinetic profile of methazolamide in blood: effect of erythrocyte carbonic anhydrase binding on drug disposition.
    AbuTarif MA; Taft DR
    Pharm Res; 2002 Apr; 19(4):551-5. PubMed ID: 12033394
    [No Abstract]   [Full Text] [Related]  

  • 4. Uptake and stereoselective binding of the enantiomers of MK-927, a potent carbonic anhydrase inhibitor, by human erythrocytes in vitro.
    Lin JH; Lin TH; Cheng H
    Pharm Res; 1992 Mar; 9(3):339-44. PubMed ID: 1614967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course and disposition of methazolamide in human plasma and red blood cells.
    Bayne WF; Tao FT; Rogers G; Chu LC; Theeuwes F
    J Pharm Sci; 1981 Jan; 70(1):75-81. PubMed ID: 6785411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions.
    Jiang S; Wang F; Zhu S; Zhang X; Guo Z; Li R; Xu Q
    Int J Pharm; 2013 May; 448(2):390-3. PubMed ID: 23541985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradation and effects of the potential mosquito larvicides methazolamide and acetazolamide in sheepshead minnow (Cyprinodon variegatus).
    del Pilar Corena M; van den Hurk P; Zhong H; Brock C; Mowery R; Johnson JV; Linser PJ
    Ecotoxicol Environ Saf; 2006 Jul; 64(3):369-76. PubMed ID: 16054216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of methazolamide concentrations in human biological fluids using high performance liquid chromatography.
    Iyer GR; Taft DR
    J Pharm Biomed Anal; 1998 Feb; 16(6):1021-7. PubMed ID: 9547705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
    Maren TH; Conroy CW; Wynns GC; Levy NS
    J Ocul Pharmacol Ther; 1997 Feb; 13(1):23-30. PubMed ID: 9029437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ocular distribution of methazolamide after corneal and scleral administration: the effect of ionization state.
    Conroy CW; Maren TH
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):565-73. PubMed ID: 9867339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Net sugar transport is a multistep process. Evidence for cytosolic sugar binding sites in erythrocytes.
    Cloherty EK; Sultzman LA; Zottola RJ; Carruthers A
    Biochemistry; 1995 Nov; 34(47):15395-406. PubMed ID: 7492539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro.
    Hasegawa T; Hara K; Hata S
    Drug Metab Dispos; 1994; 22(3):377-82. PubMed ID: 8070313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
    Fossati S; Giannoni P; Solesio ME; Cocklin SL; Cabrera E; Ghiso J; Rostagno A
    Neurobiol Dis; 2016 Feb; 86():29-40. PubMed ID: 26581638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats.
    Wong BK; Bruhin PJ; Lin JH
    Pharm Res; 1994 Mar; 11(3):438-41. PubMed ID: 8008713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The enzyme-inhibitor approach to cell-selective labelling--I. Sulphonamide inhibitors of carbonic anhydrase as carriers for red cell labelling: in vitro uptake of pIBS by human red blood cells.
    Singh J; Wyeth P
    Int J Rad Appl Instrum A; 1991; 42(3):251-9. PubMed ID: 1647382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
    Brechue WF; Maren TH
    Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic anhydrase and control of breathing: different effects of benzolamide and methazolamide in the anaesthetized cat.
    Teppema L; Berkenbosch A; DeGoede J; Olievier C
    J Physiol; 1995 Nov; 488 ( Pt 3)(Pt 3):767-77. PubMed ID: 8576866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation of choroid plexus carbonic anhydrase activity to cerebrospinal fluid formation: study of three inhibitors in cat with extrapolation to man.
    Vogh BP
    J Pharmacol Exp Ther; 1980 May; 213(2):321-31. PubMed ID: 7365692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiological measure of carbonic anhydrase in Müller cells.
    Newman EA
    Glia; 1994 Aug; 11(4):291-9. PubMed ID: 7960033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors.
    Abbate F; Casini A; Scozzafava A; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Aug; 18(4):303-8. PubMed ID: 14567544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.